Brachytherapy improves treatment in augmented women

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 17 No 12
Volume 17
Issue 12

CHICAGO-Targeted radiation of breast cancer after lumpectomy reduces treatment time from six and a half weeks to five days, while reducing pain and improving cosmetic outcome, according to a study presented at RSNA 2008 (abstract SSC19-02).

CHICAGO-Targeted radiation of breast cancer after lumpectomy reduces treatment time from six and a half weeks to five days, while reducing pain and improving cosmetic outcome, according to a study presented at RSNA 2008 (abstract SSC19-02).

Brachytherapy is particularly useful for breast cancer patients who have undergone breast augmentation. It targets cancer using radioactive “seeds” placed with catheters under CT guidance. The seeds emit high doses of radiation in a localized area, avoiding any contact with or effect on the breast implant.

“Brachytherapy treats only the cancerous portion of the breast,” said Robert R. Kuske, Jr., MD, a clinical professor of radiation oncology at the University of Arizona Health Sciences Center. “It offers augmented woman with early-stage breast cancer a potential major improvement in outcomes over mastectomy especially, but also over traditional whole-breast radiation.”

Since the radiation works from the inside out, brachytherapy lasts only five days as opposed to the six and a half weeks of whole-breast radiation.

Whole-breast radiation, the current method, can also cause scar tissue to wrap around breast implants, hardening them and causing extreme pain. The condition, known as capsular contraction, also distorts the appearance of the breast. It occurs in over half of wholebreast radiation patients.

The alternative, and the most common treatment for breast cancer patients who have had breast augmentations, is mastectomy. But for patients concerned with cosmesis, this is not a preferable option.

By localizing the radiation, Dr. Kuske was able to successfully eliminate capsular contraction in all 65 of the women treated in his study. Follow-up ranging from six months to five years, has found no breast or regional lymphatic recurrences to date.

The only limitation for this treatment is that the cancer must be caught at an early stage, Dr. Kuske said. Women with four or more positive lymph nodes or a tumor larger than 3 cm would not be good candidates for imageguided brachytherapy. Otherwise, his study shows the treatment to be quite effective.

“And the cosmetic results have been superb,” he said.

Cosmetic outcome was determined to be good to excellent in 100% of patients in Dr. Kuske’s study, with 95% judged excellent. Not a single patient suffered capsular contraction.

“This is the ultimate informal targeted delivery of radiation therapy, without exposing wide swaths of tissue to radiation exposure,” Dr. Kuske said.

Recent Videos
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Related Content